Upload
kera
View
39
Download
0
Tags:
Embed Size (px)
DESCRIPTION
PRESENTED BY DR SUDEEP CHATURVEDI MBBS, MS(OPHTHO) SR SPL(AGM) NTPC LTD HOSPITAL, BTPS, NEW DELHI 110044. INNOVATION IN PROCUREMENT OF MEDICINES AT BTPS. PROBLEMS OF PREVIOUS YEARS’ PROCUREMENTS CAUSES IDENTIFIED OVERCOMING THE AREAS OF CONCERN RESULT’S ANALYSIS CONCLUSION. OUTLINE. - PowerPoint PPT Presentation
Citation preview
PRESENTED BY DR SUDEEP CHATURVEDI MBBS, MS(OPHTHO)SR SPL(AGM)NTPC LTD HOSPITAL, BTPS, NEW DELHI 110044
PROBLEMS OF PREVIOUS YEARS’ PROCUREMENTS
CAUSES IDENTIFIED OVERCOMING THE AREAS OF CONCERN RESULT’S ANALYSIS CONCLUSION
MANY TENDERS FOR MEDICINES- 141 for 145 ITEMS POOR VENDOR RESPONSES REPEATED EXTENSIONS OF BOD MANY ORDERS ON SINGLE TENDER HIGHER COST OF PROCUREMENT LOW EXECUTION OF INDENTS TO PURCHASE
ORDERS- 103 ITEMS PROCURED SOME ITEMS SHIFTED TO DEPARTMENTAL
PROCUREMENT THROUGH PANEL PHARMACY(FIXED DISCOUNT OF 18% ON MRP)- LOW VALUE PROCUREMENT/ NO OR POOR RESPONSE
INDIVIDUAL ITEM STANDARDISATION SINGLE ITEM INDENTS RELATIVELY LOWER VALUE OF EACH INDENT POOR VENDOR RESPONSES REPEAT EXTENSIONS OF BOD MANY INDENTS DECIDED ON SINGLE TENDER
BASIS DUE TO POOR RESPONSE LOW VALUE ITEMS COULD NOT BE INDENTED-
PROCURED AT HIGHER COST ON MRP
EMD POOR VENDOR RESPONSES EMD EATING IN PROFIT MOSTLY DISTRIBUTERS QUOTING ON BEHALF OF
MANY MANUFACTURERS WITH AUTHORISATION ; SOMETIMES FOR SAME TENDER
HIGHER COST OF EMD-HIGHER COST OF PROCUREMENT/ ESTIMATED COST
DELAY IN RELEASE OF EMD DUE TO VOLUME OF FILES/PROPOSALS
INCREASED NUMBER OF INDENTS DIFFICULTY IN FOLLOW UP FOR TENDERING, TS, CS
AND PURCHASE ORDERS BY INDENTING DEPARTMENT
REPEATED MOVEMENTS OF EACH FILE TO APPROVING AUTHORITY FOR EACH DEVIATION- EXTENSION OF BOD, RELEASE OF EMD & SD, VARIATION IN QUANTITY OF PROCUREMENT, ADDITIONS OF VENDORS ETC.
LACK OF ATTENTION OF PURCHASE DEPARTMENT PERSONNEL DUE TO PROLONGED, REPEATITIVE PROCESS/ INTERRUPTIONS BY MAIN PLANT NEEDS
HIGHER COST OF PROCUREMENT POOR VENDOR RESPONSES MANY ORDERS AGAINST SINGLE/ TWO OFFERS OTHER PROJECT SUPPLY RATES NOT COMPARED STANDARDISATION NOT ON THE BASIS OF DEEP
STUDY OF MARKET TRENDS
LOW EXECUTION OF PO POOR VENDOR RESPONSES QUOTED PRICES HIGHER THAN THE LPP- ITEMS
DROPPED
SUMMARISED CAUSES OF FAILURES LOW VALUE OF TENDERS POOR VENDOR RESPONSES STANDARDISATION WITHOUT STUDY OF MARKET
TRENDS/UPDATION DELAY IN RELEASE OF MONEY(EMD/SEC DEPOSIT) POOR FOLLOW UP DUE TO LARGE VOLUME OF
FILES REPEAT EXTENSIONS
STANDARDISATION GROUP WISE STANDARDISATION OF MEDICINE
VENDORS E.G. HYPERTENSIVE , DIABETES, ANTI INFECTIVE, NUTRITION, GIT RELATED ETC
POPULAR COMPANIES FROM STANDARDISED LIST OF VENDORS INCLUDED IN A GROUP WHICH WERE FOUND TO BE HAVING LOW MRP OF PRODUCTS
PO OF OTHER PROJECTS STUDIED TO INCLUDE THE SUPPLIERS SUPPLYING PRODUCTS AT LOWER RATES
MANY VENDORS FOR EACH ITEM INCLUDED IN A GROUP
INDENTING SINGLE PURCHASE REQUISITION FOR ONE
GROUP OF MEDICINES- 18 FILES FOR ENTIRE MEDICINES
COLLECTIVE VALUE OF INDENTS INCREASED EMD REMOVED WITH APPROVAL OF CA CLOSURE REVIEW OF FILES WITH TIMELY
REMINDERS TO VENDORS ABOUT ENQUIRIES, AND BOD THRU SMS, PHONE & E MAILS
TENDER FILLING MADE EASY- SINGLE PAGE TENDER FILLING; MENTIONING THE ITEM CONSTITUENTS, RATE OFFERRED, MRP, PACK SIZE AND BRAND NAME AND SUPPLY AGENT.
GROUP NO OF ITEMS INDENTED ITEMS ORDERED VALUE OF POS VENDORS FOR PO
ANTIDIABTIC 8 8 265245(397867) 1.M/S PANACEA BIOTECH (2 NO.) (RS. 36,000/-)2.M/S IPCA LABORATORIES (1 NO.) (RS. 1,17,000/-
3.M/S USV LTD.(3 NO.) (RS. 18,745/-)4.M/S GLANMARK PHARMA (2 NO.) (RS. 93,500/-)
PO DTD. 29.10.2010NUTRITION
&METABOLISUM13 12 228766(243349) 1.M/S KARNATAKA ANTIBIOTIC(2 NO.) (RS. 38,400/-
2.M/S ARISTO PHARMA (1 NO.) (RS. 53,340/-)3.M/S LIFE STAR PHARMA (1 NO.) (RS. 5,105/-)
4.M/S AFD LTD. (4 NO.) (RS. 67,257/-)5.M/S INDOCO REMIDIES (2 NO.) (RS. 27,650/-)6.M/S FRANCO INDIAN (1 NO.) (RS. 19,014/-)
7.M/S GUFIC BIOSCIENCE (1 NO.) (RS. 18,000/-)PO DTD. 05.10.2010
GIT 15 15 392977(589465) 1.M/S J.B. CHEMICALS (3 NO.) (RS. 77,500/-)2.M/S WIN MEDICARE (1 NO.) (RS. 48,333/-)
3.M/S WALLACE PHARMA (2 NO.) (RS. 90,800/-)4.M/S PIRAMAL HEALTHCARE(3 NO.) (RS. 10,566.70/-)
5.M/S IPCA LAB(1 NO.) (RS. 11,250/-)6.M/S MANKIND PHARMA(1 NO.) (RS. 3,828/-)
7.M/S GUFIC BIOSCIENCE(4 NO.) (RS. 1,50,700/-)PO DTD. 30.10.2010
CARDIOVASCULAR 15 15 163248(244872) 1.M/S USV LTD. (6 NO.) (RS. 84,942/-)2.M/S PIRAMAL HEALTHCARE(5 NO.) (RS. 44,406.80/-)
3.M/S IPKA LABORATORIES(3 NO.) (RS. 27,400/-)4.M/S EMCURE PHARMA(1 NO.) (RS. 6,500/-)
PO DTD. 09.09.2010ANALGESIC & ANTIPYRITIC
14 13 162999(278137.50)
1.M/S PIRAMAL HEALTH CARE(6 NO.) (RS. 81,984/-)2.M/S IPCA LAB (3 NO.) (RS. 46,630/-)
3.M/S KARNATAKA ANTIBIOTIC (2 NO.) (RS.11,520/-)4.M/S GLAXO SMITHKLINE (2 NO.) (RS. 22,865/-)
PO DTD. 05.10.2010
ONLY 19 INDENTS FOR 173 ITEMS EASY FOLLOW UP ALL BUT ONE INDENT OPENED ON BOD WITHOUT
EXTENSIONS( DENTAL PROCEDURE ITEMS PROCURED THROUGH COMM PURCHASE)
ONLY ONE ITEM ORDERED ON SINGLE TENDER ALL ORDERS AGAINST ONE INDENT ON SAME DATE RATES OFFERED LOWEST AMONG ALL PROJECTS AS
AVAILABLE IN SAP(FOR RECENT PO OF SAME ITEMS) DISTRIBUTION OF ORDERS TO MULTIPLE VENDORS
Cost of medicine procurement
YEAR COST % OF ITEMS AVERAG
E COST /ITEM
REMARKS
2008-09 38,32,434.00 71%(103/145) 37208.10
2009-10 42,26,014.0 89%(151/170) 27986.10 QTY INCREASED
2010-11 50,38,014.33 93%(158/170) 31886.10 QTY INCREASED
•TOTAL QUANTITY OF EACH ITEM INCREASED BASED ON CONSUMPTION TO REDUCE NON AVAILABILITY IN SUBSEQUENT YEARS•THE COST OF EACH ITEM /UNIT REDUCED IN EACH SUBSEQUENT YEARS•MOST ITEMS PROCURED AT LOWER RATE THAN AVAILABLE SAP RATES ALL OVER NTPC LTD
THE FACTORS FOR INCREASED COMPLIANCE:
INCREASED VALUE OF INDENTS/ INCREASED VENDOR RESPONSES
REDUCED VOLUME OF WORK/ EASY FOLLOW UP RESULT OF PROCEDURE:
INCREASED AVAILABILITY OF PRODUCTS LOW VALUE OF PROCUREMENT DUE TO
INCREASED COMPITITION INCREASED SATISFACTION DUE TO INCREASED
AVAILABILITY OF MEDICINES/ REDUCED NON AVAILABILITY